Humana's Big Rebound: What $256 Million More Members Means for Investors

Humana just jumped nearly 13% in a matter of days. 

That's not something you see every day from a healthcare giant worth over $30 billion.

Here's what we know. 

The company announced a sharp increase in members enrolled in higher-rated Medicare Advantage plans for 2026. 

We're talking about 4.5-star offerings, the kind that actually pay better. 

Yeah, they confirmed their 2025 earnings guidance right when investors needed to hear it most.

That matters more than you might think.

Right now, Humana $HUM ( ▲ 1.99% ) trades at around $295.49 per share. 

Let us put that in context for you.

Royal Bank Of Canada raised their price target on shares of Humana from $283.00 to $322.00 and gave the stock an "outperform" rating in a research note on Thursday, August 21st. 

Sanford C. Bernstein raised their price target on shares of Humana from $269.00 to $341.00 and gave the stock an "outperform" rating in a research note on Friday, September 5th. 

Morgan Stanley decreased their price target on shares of Humana from $290.00 to $277.00 and set an "equal weight" rating on the stock in a research note on Thursday, July 31st.

But here's where it gets interesting, the most optimistic analysts see it hitting $353.

Think of Medicare Advantage star ratings like a credit score for health plans. Higher stars mean better government payments. 

Humana's 2026 enrollment in these premium plans jumped significantly, with about 1.2 million members now in plans rated 4 stars or above.

Compare that to where they were just months ago and you'll see why investors perked up.

That's exactly what Humana is betting on.

But Here's the Thing

This comeback story isn't without risks. Legal challenges over Medicare Advantage ratings are still hanging around. Audit protocols keep changing. These aren't small concerns, they could absolutely impact profit margins down the road.

And let's be real. One-year returns barely broke even. This surge looks good on paper, but long-term shareholders are still waiting to get back to where they were.

Wall Street remains cautiously optimistic. 

Several firms maintained "outperform" ratings after the announcement, citing demographic trends working in Humana's favor. 

With 10,000 Americans turning 65 every day, Medicare Advantage isn't going anywhere.

One healthcare analyst put it simply: "Humana positioned itself well heading into a strong enrollment cycle. The question is whether they can maintain margin discipline while growing."

At 22.66 times earnings and yielding 1.20% in dividends, Humana isn't exactly a bargain basement play. But it's not wildly overpriced either. 

Is this the start of a sustained recovery or just a relief rally? 

That depends entirely on execution over the next 12 months. Medicare Advantage remains complicated, competitive, and heavily regulated.

Just know what you're buying. This isn't a growth stock anymore, it's a steady-as-she-goes play that needs to prove it can navigate choppy regulatory waters.

Worth watching? Absolutely. 

Worth buying today? That depends on your risk tolerance and what else is in your portfolio.

Disclaimer: This is not financial advice. Do your own research and consult a qualified financial advisor before investing.